Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q3 FY2021 Earnings Presentation
28 slides from Advanced Enzyme Technologies's earnings presentation, Feb 12, 2021
Slide 1: Outcome of Board Meeting held on February 12, 2021
enzymesWhere ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051 018 Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200, Fax: +91-22-2583 5159 Email: info@advancedenzymes.com, www.advancedenzymes.com February 12, 2021
Slide 2: Limited review report (consolidated)
B S R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing, Telephone: +91 22 6257 1000 Nesco IT Park 4, Nesco Center, Fax: +91 22 6257 1010 Western Express Highway, Goregaon (East), Mumbai - 400 063 Limited review report To Board of Directors of Advanced Enzyme Technologies L
Slide 3: Limited review report (continued)
B S R & Co. LLP Advanced Enzyme Technologies Limited 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to b
Slide 4: Statement of unaudited consolidated financial results
Advanced Enzyme Technologies Limited CIN No.: L24200 MH1989PLC051018 Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India. Tel No:91-22-41703220 Fax No: +91-22-25835159 Website: www.advancedenzymes.com, Email Id :sanjay@advan
Slide 5: Notes to consolidated financial results
Advanced Enzyme Technologies Limited CIN No.: L24200MH1989PLC051018 Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India. Tel No:91-22-41703220 Fax No: +91-22-25835159 Website: www.advancedenzymes.com, Email Id : sanjay@advan
Slide 6: Limited review report (standalone)
B S R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing, Telephone: +91 22 6257 1000 Nesco IT Park 4, Nesco Center, Fax: +91 22 6257 1010 Western Express Highway, Goregaon (East), Mumbai - 400 063 Limited review report To Board of Directors of Advanced Enzyme Technologies L
Slide 7: Statement of unaudited standalone financial results
Advanced Enzyme Technologies Limited CIN No.: L24200MH1989PLC051018 Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India. Tel No:91-22-41703220 Fax No: +91-22-25835159 Website: www.advancedenzymes.com, Email Id :sanjay@advanc
Slide 8: Notes to standalone financial results
Advanced Enzyme Technologies Limited CIN No.: L24200MH1 989PLC051 018 Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India. Tel No:91-22-41703220 Fax No: +91-22-25835159 Website: www.advancedenzymes.com, Email Id :sanjay@adva
Slide 9: Earnings Release: Q3 and Nine Months ended December 2020
enzymes Where ENZYME is Life FOR IMMEDIATE RELEASE EARNINGS RELEASE Date: February 12, 2021 Advanced Enzyme Technologies Limited announces Financial Results for Third Quarter and Nine Months ended December 2020 Mumbai, India: Thursday, February 12, 2021 – Advanced Enzyme Technologies Limited (Advanc
Slide 10: About Advanced Enzymes
enzymes Where ENZYME is Life solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. Our
Slide 11: I ir
I /A enzymes Whore ENZYME is Lite Advanced Enzyme Technologies Limited Earnings Presentation | Q3FY21 . i. ' A i V> i-|r. ir / v r * vv * 9 VI V / /i ill v L* v £1 i I %•' 4 r v V<
Slide 12: Disclaimer
Disclaimer Enzymes Where ENZYME is Lite This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materiall
Slide 13: Company Overview
Company Overview Enzymes Where ENZYME is Lite What are r 3 LlJ enzymes? . Sim1 A m ~nT .-SM m- % J t rf Wi Enzymes are natural protein molecules that act as catalysts n ’•a .0 4 ll .r M ! HI -J LH dL, ' .>ÿÿ within living cells, produced by if all living organisms. Function as * « specialized cataly
Slide 14: A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Enzymes Where ENZYME is Lite R&D Units – 6 } Manufacturing Units – 7 India – 5 I USA - 2 t India – 4 | USA – 1 | Germany –1 REVENUE (₹ mn) 4,440 T1 st Indian enzyme company Y2 nd Highest market share in Y2 nd Listed integrated 2,938 India e
Slide 15: Results Summary – Q3FY21 (Consolidated)
Results Summary – Q3FY21 (Consolidated) Y-o-Y Enzymes Where ENZYME is Lite *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) T20,° 1,377 26% 664 %&l° 1,119 529 443 346 Q3FY20 Q3FY21 Q3FY20 Q3FY21 Q3FY20 Q3FY21 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing 30% o -24% Q3FY21
Slide 16: Revenue Split – Q3FY21 vs. Q3FY20
Revenue Split – Q3FY21 vs. Q3FY20 Enzymes Where ENZYME is Lite Q3FY21 Q3FY20 Product Category-wise (%) Product Category-wise (%) 13% 8% 15% 13% 79% 72% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 3% 2% 5% 39% 42
Slide 17: Results Summary – 9MFY21 (Consolidated)
Results Summary – 9MFY21 (Consolidated) Y-o-Y Enzymes Where ENZYME is Lite *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 10% 17% 3,686 l5% 1,766 3,337 1,536 1,177 1,004 9MFY20 9MFY21 9MFY20 9MFY21 9MFY20 9MFY21 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing 16% -24% o 9
Slide 18: Revenue Split – 9MFY21 vs. 9MFY20
Revenue Split – 9MFY21 vs. 9MFY20 Enzymes Where ENZYME is Lite 9MFY21 9MFY20 Product Category-wise (%) Product Category-wise (%) 13% 9% 15% 12% 78% 73% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 4% 5% 42% 44
Slide 19: Profit & Loss (Consolidated) – Q3FY21 & 9MFY21
Profit & Loss (Consolidated) – Q2FY21 & 9MFY21 Enzymes Where ENZYME is Lite ₹ in Million except per share data Q3FY21 Q2FY21 Q3FY20 Y-o-Y 9MFY21 9MFY20 Particulars Y-o-Y (%) Unaudited Unaudited Unaudited (%) Unaudited Unaudited Income from Operations 1,377 1,204 1,119 23% 3,686 3,337 10% Expenses 77
Slide 20: Balance Sheet (Consolidated) – 9MFY21
Balance Sheet (Consolidated) – 9MFY21 Enzymes Where ENZYME is Lite ₹ in Million 9MFY21 9MFY20 Particulars Unaudited Audited Assets Property, plant and equipment 1,993 2,021 Capital work-in-progress 143 176 Intangible assets 575 591 Goodwill 2,884 2,792 Other non-current assets 193 184 Current assets
Slide 21: Results Summary – FY20
Results Summary – FY20 Enzymes Where ENZYME is Lite *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 6% AA% A 5% 4,440 2,023 4,196 1,819 1,330 1,159 FY19 FY20 FY19 FY20 FY19 FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing o 9% -24% FY20 FY19 536 493 o 2% FY20 FY19 3,21
Slide 22: Revenue Split – FY20
Revenue Split – FY20 Enzymes Where ENZYME is Lite FY20 FY19 Product Category-wise (%) Product Category-wise (%) 13% 12% 12% 12% 75% 76% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 6% 4% 42% 49% 40% 43% 7% 5%
Slide 23: Profit & Loss (Consolidated) – FY20
Profit & Loss (Consolidated) – FY20 Enzymes Where ENZYME is Lite ₹ in Million except per share data FY20 FY19 Particulars Y-o-Y (%) Audited Audited Income from Operations 4,440 4,196 6% Expenses 2,675 2,587 3% Profit from Operations before Other Income, Finance Costs and 1,765 1,609 10% Exceptional
Slide 24: Balance Sheet (Consolidated) – FY20
Balance Sheet (Consolidated) – FY20 Enzymes Where ENZYME is Lite ₹ in Million FY20 FY19 Particulars Audited Audited Assets Property, plant and equipment 2,042 1,618 Capital work-in-progress 101 105 Intangible assets 646 622 Goodwill 2,941 2,715 Other non-current assets 195 183 Current assets 3,813 2
Slide 25: Strong Financial Performance – FY20
Strong Financial Performance – FY20 WPS Where ENZYMEis Life ₹ in Million Revenue from Operations EBIDTA & EBIDTA Margin (%) 4,440 2,500 47% 43% 46% 50% 3,957 4,196 42% Hill Hill 48% 2,000 3,431 45% 46% 2,938 1,500 1,654 44% 1,534 2,023 1,000 1,389 42% 1,819 40% 500 38% 0 36% FY 16 FY 17 FY 18 FY 19
Slide 26: Strong Financial Performance – FY20
Strong Financial Performance – FY20 Enzymes Where ENZYME is Lite Net Working Capital (Days) Net Worth (₹ mn) 8,396 119 6,788 115 5,591 112 4,640 108 105 2,781 FY 16 FY 17 FY 18 FY 19 FY 20 FY 16 FY 17 FY 18 FY 19 FY 20 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.4 27% 27% 24% 21% 28% 19% 18% 19%
Slide 27: Shareholder Information
Shareholder Information Enzymes Where ENZYME is Lite Top 5 Institutional Holders (As on 05th February 2021) Stock Data (As on 11th February 2021) Institutions OS (%) ORBIMED ASIA III MAURITIUS 12.09 #1 Market Capitalization (₹) 41,623 mn HDFC AMC 5.63 Shares Outstanding 111.72 mn NALANDA INDIA EQUIT
Slide 28: Thank You
Advancecl enzymes Where ENZYME is Life Thank You Advanced Enzyme Technologies Limited Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91-22-4170 3200 Web: www.advancedenzymes.com Fax: + 91-22-25835159 GOPINATH PARSIKBANK 9 9 Green Rd 9 9 Nav Go
Advanced Enzyme Technologies — Q3 FY2021 Earnings Presentation on 6ix